We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+50.39%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$3.65B
AUM Growth
+$1.23B
Cap. Flow
+$333M
Cap. Flow %
9.14%
Top 10 Hldgs %
23.51%
Holding
147
New
14
Increased
82
Reduced
11
Closed
4

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$36.8M
2
UNH icon
UnitedHealth
UNH
+$30.1M
3
RPRX icon
Royalty Pharma
RPRX
+$24.7M
4
NVAX icon
Novavax
NVAX
+$21.8M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$19.5M

Top Sells

Rank Stock Value
1
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$42.7M
2
ISRG icon
Intuitive Surgical
ISRG
+$17.5M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$6.7M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.68M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.96M

Sector Composition

Rank Sector Weight
1 Healthcare 96.99%
2 Miscellaneous 1.37%
3 Consumer Staples 1.09%
4 Consumer Discretionary 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNST
76
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$15.5M 0.43%
515,680
+282,180
+121% +$10.2M
GH icon
77
Guardant Health
GH
$23.6B
$15.4M 0.42%
190,000
– –
FOLD
78
DELISTED
Amicus Therapeutics
FOLD
$15.3M 0.42%
1,016,821
+16,821
+2% +$205K
CVET
79
DELISTED
Covetrus, Inc. Common Stock
CVET
$15M 0.41%
837,500
+816,817
+3,949% +$10.7M
BHVN
80
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$14.9M 0.41%
203,817
+3,817
+2% +$203K
JNJ icon
81
Johnson & Johnson
JNJ
$644B
$14.8M 0.41%
105,000
– –
GWPH
82
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$14.7M 0.4%
120,043
+90,043
+300% +$10.2M
DVAX
83
DELISTED
Dynavax Technologies
DVAX
$14.7M 0.4%
1,660,120
+85,120
+5% +$430K
SYRE icon
84
Spyre Therapeutics
SYRE
$8.02B
$14.7M 0.4%
63,621
+31,621
+99% +$6.02M
RDUS
85
DELISTED
Radius Health, Inc.
RDUS
$13.7M 0.38%
1,003,259
+28,259
+3% +$389K
MNTA
86
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$13.3M 0.37%
400,000
– –
TGTX icon
87
TG Therapeutics
TGTX
$8.12B
$13.3M 0.36%
+682,926
New +$11M
PPD
88
DELISTED
PPD, Inc. Common Stock
PPD
$13.1M 0.36%
487,500
+37,500
+8% +$937K
CNMD icon
89
CONMED
CNMD
$1.41B
$13M 0.36%
180,000
– –
KYNB
90
Kyntra Bio
KYNB
$31.5M
$12.8M 0.35%
12,618
+378
+3% +$351K
DCPH
91
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$12.5M 0.34%
209,829
-125,171
-37% -$6.7M
HCAT icon
92
Health Catalyst
HCAT
$129M
$12.4M 0.34%
425,000
– –
TBIO
93
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$11.8M 0.33%
661,268
-163,732
-20% -$2.47M
BFAM icon
94
Bright Horizons
BFAM
$3.28B
$11.5M 0.32%
+98,500
New +$11.2M
RYTM icon
95
Rhythm Pharmaceuticals
RYTM
$6.66B
$11.4M 0.31%
512,111
+12,111
+2% +$236K
ZGNX
96
DELISTED
Zogenix, Inc.
ZGNX
$11.2M 0.31%
415,982
+15,982
+4% +$441K
IMVT icon
97
Immunovant
IMVT
$7.57B
$11M 0.3%
452,319
+202,319
+81% +$4.34M
RIGL icon
98
Rigel Pharmaceuticals
RIGL
$829M
$10.8M 0.3%
589,764
+39,764
+7% +$715K
MYOV
99
DELISTED
Myovant Sciences Ltd.
MYOV
$10.5M 0.29%
508,411
+8,411
+2% +$114K
NVCR icon
100
NovoCure
NVCR
$1.88B
$10.4M 0.28%
175,000
– –
2 3
4
5 6

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Rock Springs Capital Management held 147 positions worth $3.65B, up 51% from $2.42B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management deployed $333M of net new capital in Q2 2020, opening 14 new positions and adding to 82 existing holdings. Its largest new stake was Royalty Pharma: 500,000 shares worth $24.3M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Intuitive Surgical, an estimated $17.5M trimmed.

  • Rock Springs Capital Management's largest Q2 2020 buy was Royalty Pharma: 500,000 shares worth $24.3M.
  • Rock Springs Capital Management added most to Centene in Q2 2020, an estimated $36.8M increase.
  • Rock Springs Capital Management's biggest Q2 2020 reduction was Intuitive Surgical, cutting an estimated $17.5M.
  • Rock Springs Capital Management fully exited Forty Seven, Inc. Common Stock in Q2 2020, selling an estimated $42.7M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $3.65B portfolio in Q2 2020.
  • Rock Springs Capital Management opened 14 new positions and closed 4 in Q2 2020.
  • Rock Springs Capital Management's portfolio value rose 51% quarter-over-quarter to $3.65B.

Based on Rock Springs Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.